Litcius/Paper detail

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Ankit Patel, Ashish Verma

2020JAMA402 citationsDOI

Abstract

Matt Arentz, MD; Eric Yim, MD; Lindy Klaff, MD; Sharukh Lokhandwala, MD, MSc; Francis X. Riedo, MD; Maria Chong, MD; Melissa Lee, MD

Topics & Concepts

MedicineAngiotensin Receptor BlockersCoronavirus disease 2019 (COVID-19)Angiotensin-converting enzymePharmacologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakAngiotensin-converting enzyme 2Angiotensin IIEnzymeReceptorInternal medicineBiochemistryInfectious disease (medical specialty)DiseaseBlood pressureChemistryOutbreakCOVID-19 Clinical Research StudiesRenin-Angiotensin System StudiesVitamin C and Antioxidants Research
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers | Litcius